Showing 4011-4020 of 6035 results for "".
- Bausch + Lomb Recycles Over 625,000 Pounds of Eye Care Materialshttps://modernod.com/news/bausch-lomb-recycles-over-625000-pounds-of-eye-care-materials/2482745/Bausch + Lomb announced a sustainability milestone: its 'ONE by ONE' and 'Biotrue Eye Care' recycling programs have collectively diverted more than 103 million units, or 625,026 pounds, of used contact lenses and eye care materials fr
- Applications Being Accepted for the 2025 Ramin Tadayoni Awardhttps://modernod.com/news/applications-being-accepted-for-the-2025-ramin-tadayoni-award/2482740/Oculis, in collaboration with EURETINA, announced that applications are now being accepted for the 2025 Ramin Tadayoni Award. The Ramin Tadayoni Award continues its legacy through EURETINA and has been supported by Oculis as a lasting tribute
- MST Enters Strategic Partnership with Mani to Distribute Ophthalmic Surgical Blade Portfolio in the UShttps://modernod.com/news/microsurgical-technology-mst-enters-strategic-partnership-with-mani-to-distribute-ophthalmic-surgical-blade-portfolio-in-the-us/2482739/Microsurgical Technology (MST) announced a strategic partnership with Mani Inc. under which MST will serve as a distributor of Mani’s ophthalmic surgical blade portfolio in the United States. The deal is supported by the establishment of Mani Medical America, the US
- Prevent Blindness Says West Virginia State House Bill Would Imperil Children’s Visionhttps://modernod.com/news/prevent-blindness-says-west-virginia-state-house-bill-would-imperil-childrens-vision/2482738/Prevent Blindness published a letter on its website Tuesday calling on the West Virginia State House to reject
- Andrew Chang Joins BVI Medical as Chief Commercial Officerhttps://modernod.com/news/andrew-chang-joins-bvi-medical-as-chief-commercial-officer/2482735/BVI Medical announced the appointment of Andrew Chang to the newly created role of Chief Commercial Officer. Mr. Chang will lead the company’s global sales, global marketing, and commercial excellence teams and will report directly to President and CEO Shervin Korangy. Mr. Ch
- Eye Foundation of America Hosts Fundraising Galahttps://modernod.com/news/eye-foundation-of-america-hosts-fundraising-gala/2482734/On April 12, the Eye Foundation of America is hosting a Spring fundraiser gala in New Rochelle, New York. Under the leadership of Surendra Sharma, MD and Rachana Shukla, MD, the group hopes to raise funds to help support a new state-of-the-art green hospital in India, as well
- Outlook Therapeutics Announces Acceptance of Resubmitted BLA by FDA for ONS-5010 as a Treatment for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-acceptance-of-resubmitted-bla-by-fda-for-ons-5010-as-a-treatment-for-wet-amd/2482733/Outlook Therapeutics announced that the FDA has acknowledged receipt of the resubmission of the biologics license application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD. The FDA has determined that the BLA
- Oculis Completes Enrollment in Both DIAMOND Phase 3 Trials of OCS-01 in DMEhttps://modernod.com/news/oculis-completes-enrollment-in-both-diamond-phase-3-trials-of-ocs-01-in-dme/2482732/Oculis Holding said it has completed enrollment in both phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in DME. The trials are designed as pivotal registration studies to support global marketing applications including NDA submission and approval by t
- Atsena Therapeutics Secures $150 Million to Advance Investigational Ocular Gene Therapyhttps://modernod.com/news/atsena-therapeutics-secures-150-million-to-advance-investigational-ocular-gene-therapy/2482726/Atsena Therapeutics has closed an oversubscribed $150 million Series C financing, which will be used to advance Atsena’s lead gene therapy program, ATSN-201, aimed at treating X-linked retinoschisis (XLRS). Additionally, the funds will support Atsena’s preclinic
- Alcon Acquires Majority Interest in Aurion Biotechhttps://modernod.com/news/alcon-acquires-majority-interest-in-aurion-biotech-to-advance-cell-therapy-for-corneal-endothelial-disease/2482718/Alcon announced it has acquired a majority interest in Aurion Biotech, a clinical-stage company developing cell therapies to treat eye diseases. Financial terms of the deal were not disclosed.